Sculptor Capital’s CorMedix CRMD Stock Holding History

Sculptor Capital’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-335,900	Closed	-$2.28M	–	415
2026 Q1	$2.28M	Buy	+335,900	New	+$2.48M	0.02%	228

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Sculptor Capital's CRMD Position: Q2 2026 in Review

Sculptor Capital sold out of CorMedix (CRMD) in Q2 2026, closing a stake of 335,900 shares — an estimated $2.28M sold.

Sculptor Capital first reported a position in CRMD in Q1 2026 and held it in 1 quarter. The position peaked at $2.28M in Q1 2026. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Sculptor Capital reported no remaining CorMedix position as of Q2 2026 after selling out during the quarter.
Sculptor Capital sold 335,900 CorMedix shares in Q2 2026, an estimated $2.28M.
Sculptor Capital first reported a position in CorMedix in Q1 2026 and held it in 1 quarter.
Sculptor Capital's CorMedix position peaked at $2.28M in Q1 2026.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Sculptor Capital's 13F filing for Q2 2026, filed 14 Aug 2026.